Study of the Medullary Microenvironment in Acute Childhood Leukemia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-15
SponsorUniversity Hospital, Tours
About this trial
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.
Eligibility criteria
Qualifiers
Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
Not having received prior hematological treatment
Aged 1 to 15 years old
Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
Disqualifiers
Patient under 1 year old and over 15 years old.
Contraindication to myelogram.
Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
Trial design
Treatments tested in this trial
- Biological sampling in patients
- Biological sampling in control patients
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov